At this moment, there are significant investing opportunities in healthcare, Jim Flynn of Deerfield Partners said at the Invest for Kids Conference in Chicago Wednesday. Yet Valeant Pharmaceuticals is not one of them, he emphatically asserted as he outlined a potential relative value trade when he recommended a long investment in Horizon Pharmaceuticals. Flynn: Valeant pushes financial structuring to its limit and pricing issues are more a statement on individual companies than pharma industry as a whole Deerfield Partners is a well-regarded healthcare specialty hedge fund that has delivered to investors 38 times their original investment since their founding in…
On This Page
- Flynn: Valeant pushes financial structuring to its limit and pricing issues are more a statement on individual companies than pharma industry as a whole
- Flynn: Drug pricing issue is “outrageous” and won’t go away unless specific companies change their pricing policies
- Flynn: Valeant has patent and leverage issues and is paying down outstanding debt is only one potential path, many of which are negative
This content is exclusively for paying members of Hedge Fund Alpha
Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha
Don’t have an account?
Subscribe now and get 7 days free!
